Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 6/20 | 0.42 |
| ▸ | PKM | P14618 | 3/20 | 0.41 |
| ▸ | MMP1 | P03956 | 3/20 | 0.40 |
| ▸ | MMP8 | P22894 | 2/20 | 0.40 |
| ▸ | MMP2 | P08253 | 4/20 | 0.38 |
| ▸ | MMP9 | P14780 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | PKLR | P30613 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21600738 | 0.85 | ALDH1A1 (0.39) | PKMALDH1A1PKLR | |
| SCHEMBL30662156 | 0.85 | CYP3A4 (0.37) | LMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL21600743 | 0.85 | CYP3A4 (0.37) | LMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL21600725 | 0.84 | DDB1 (0.41) | MAPTSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL21600717 | 0.84 | L3MBTL1 (0.38) | MMP2LMNAALDH1A1HTT | |
| SCHEMBL24246859 | 0.84 | GAA (0.38) | MMP2LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL21600737 | 0.84 | PSEN1 (0.40) | MMP2LMNASMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL21600709 | 0.84 | PSIP1 (0.36) | PKMLMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL29457734 | 0.83 | CA2 (0.42) | LMNASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL24246845 | 0.82 | PTGS2 (0.36) | MMP13MMP1MMP8MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247977-B2 | Compound and use thereof in synthesis of brivaracetam intermediate and crude drug | FUJIAN HAIXI PHARMACEUTICALS CO., LTD. (CN) | 2022-02-15 | — | — | US | disclosed |
| US-11247977-B2 | Compound and use thereof in synthesis of brivaracetam intermediate and crude drug | FUJIAN HAIXI PHARMACEUTICALS CO., LTD. (CN) | 2022-02-15 | — | — | US | disclosed |
| EP-3798211-A1 | COMPOUND AND USE THEREOF IN SYNTHESIS OF BRIVARACETAM INTERMEDIATE AND CRUDE DRUG | Fujian Haixi Pharmaceuticals Co., Ltd (CN) | 2021-03-31 | — | — | EP | disclosed |
| WO-2019242692-A1 | COMPOUND AND USE THEREOF IN SYNTHESIS OF BRIVARACETAM INTERMEDIATE AND CRUDE DRUG | 福建海西新药创制有限公司 | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247977-B2 | Compound and use thereof in synthesis of brivaracetam intermediate and crude drug | CYP3A43, POR, CYP2C19 | MMP13 2424/4885PKM 32/4885MMP1 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.